People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharma, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2024 |
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2019 |
| Affinia Therapeutics Inc. | — | Pharma | Series D+ | $170.1M | $99.8M | 2020 |
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
| Inozyme Pharma, Inc. | — | Pharmaceuticals | Series C | $116.2M | $2.4B | 2017 |
| Senti Biosciences, Inc. | — | Biotechnology | Series B | $77.0M | $222.0M | 2024 |
| Rhythm Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.0M | $765.1M | 2010 |
| Code Biotherapeutics, Inc. | — | Other Health Care | Series B | $47.5M | $465.8M | 2022 |
| Brenig Therapeutics, Inc. | — | Biotechnology | Series B | $30.0M | $210.3M | 2024 |
| Satori Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $22.3M | $464.6M | 2010 |
| Sorriso Pharmaceuticals, Inc. | — | Biotechnology | Series B | $21.3M | $449.4M | 2021 |
| Rhythm Holding Company, LLC | — | Pharmaceuticals | Series A | $11.0M | $340.7M | 2013 |
Edward Mathers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward Mathers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ed Mathers | 3 | 11 |
| Keith Gottesdiener | 3 | 4 |
| Michael Grey | 2 | 10 |
| Bart Henderson | 2 | 3 |
| Lou Tartaglia | 2 | 3 |
| Christian De La Tour | 2 | 2 |
| Peter Barrett | 1 | 18 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Robert Weisskoff | 1 | 12 |
| Todd Foley | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Chau Khuong | 1 | 9 |
| Robert Johnson | 1 | 9 |
| James Collins | 1 | 8 |
| Alex Kolicich | 1 | 8 |
| Daniel Lynch | 1 | 7 |
| David Schnell | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Elaine Jones | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.